Literature DB >> 8755646

Liver cirrhosis induces renal and liver phospholipase A2 activity in rats.

B S Vishwanath1, F J Frey, G Escher, J Reichen, B M Frey.   

Abstract

Maintenance of renal function in liver cirrhosis requires increased synthesis of arachidonic acid derived prostaglandin metabolites. Arachidonate metabolites have been reported to be involved in modulation of liver damage. The purpose of the present study was to establish whether the first enzyme of the prostaglandin cascade synthesis, the phospholipase A2(PLA2) is altered in liver cirrhosis induced by bile duct excision. The mRNA of PLA2(group I and II) and annexin-I a presumptive inhibitor of PLA2 enzyme was measured by PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal standard. The mean mRNA ratio of group II PLA2/GAPDH was increased in liver tissue by 126% (P < 0.001) and in kidney tissue by 263% (P < 0.006) following induction of liver cirrhosis. The increase in group II PLA2 mRNA in cirrhotic animals was reflected by an increase in PLA2 protein and enzyme activity in both liver and kidney tissues. Since the mRNA of group I PLA2 was not detectable and Group IV PLA2 activity measured in liver and kidney tissue samples was very low and not changed following induction of cirrhosis, it is likely that the major PLA2 activity measured in liver and kidney corresponds to group II PLA2 enzyme. The mean mRNA ratio of annexin-I/GAPDH was increased in liver tissue by 115% (P < 0.05) but unchanged in kidney tissue following induction of cirrhosis. The protein content of annexin-I and -V were not affected by bile duct excision in liver and kidney tissue indicating that upregulation of group II PLA2 activity was not due to downregulation of annexin-I or -V. Group II PLA2 activity of glomerular mesangial cells stimulated by interleukin-1 beta was enhanced by bile juice and various bile salts. In conclusion, activity of group II PLA2 is upregulated partly due to enhanced transcription and translation in cirrhosis and is furthermore augmented by elevated levels of bile salts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755646      PMCID: PMC507439          DOI: 10.1172/JCI118801

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  73 in total

1.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

2.  Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity.

Authors:  B P Wallner; R J Mattaliano; C Hession; R L Cate; R Tizard; L K Sinclair; C Foeller; E P Chow; J L Browing; K L Ramachandran
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

3.  Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis.

Authors:  F Wong; D Massie; P Hsu; F Dudley
Journal:  Gastroenterology       Date:  1994-03       Impact factor: 22.682

4.  Role of eicosanoids in the control of renal function in severe hepatic disease.

Authors:  M J Dunn
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

5.  Leukotrienes as mediators in frog virus 3-induced hepatitis in rats.

Authors:  W Hagmann; A M Steffan; A Kirn; D Keppler
Journal:  Hepatology       Date:  1987 Jul-Aug       Impact factor: 17.425

6.  Haemodialysis activates phospholipase A2 enzyme.

Authors:  B S Vishwanath; C A Fux; D E Uehlinger; B M Frey; R C Franson; F J Frey
Journal:  Nephrol Dial Transplant       Date:  1996-01       Impact factor: 5.992

7.  Tissue eicosanoids and vascular permeability in rats with chronic biliary obstruction.

Authors:  N Ohara; N F Voelkel; S W Chang
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis.

Authors:  M M Parker; J H Shelhamer; C Natanson; D W Alling; J E Parrillo
Journal:  Crit Care Med       Date:  1987-10       Impact factor: 7.598

9.  Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease.

Authors:  R D Zipser; J C Hoefs; P F Speckart; P K Zia; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

10.  Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; M Mauri; F Ribera; F Navarro-López; J Rodés
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

View more
  3 in total

1.  Cytosolic phospholipase A(2)α protects against Fas- but not LPS-induced liver injury.

Authors:  Guiying Li; Weina Chen; Chang Han; Tong Wu
Journal:  J Hepatol       Date:  2011-04-14       Impact factor: 25.083

2.  Inhibition of secretory phospholipase A(2) enzyme by bilirubin: a new role as endogenous anti-inflammatory molecule.

Authors:  Noor Mohamed Jameel; Brigitte M Frey; Felix J Frey; T Veerabasappa Gowda; Bannikuppe S Vishwanath
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

3.  Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle.

Authors:  G Escher; I Galli; B S Vishwanath; B M Frey; F J Frey
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.